OnQuality Pharmaceuticals Expands Part 2 of the NOVA-II Phase 2 Clinical Trial to China and India
Newsroom




- Nov 10, 2022
Targeted Oncology First Patient With VEGFRi-Associated Hand-Foot Skin Reaction Enrolled in NOVA-II

- Nov 9, 2022
Clinical Trials Arena I OnQuality enrols first subject in Phase II HFSR therapy trial


- Nov 8, 2022
OnQuality Pharmaceuticals Announces Enrollment of First Patient in Part 2 of the NOVA-II Phase 2


- Oct 13, 2022
OnQuality Pharmaceuticals to Present Two Posters at the 34th EORTC-NCI-AACR Symposium


- Aug 2, 2022
Behind Biotech I Hong Tang on Traditional Chinese Medicine and Targeted Cancer Supportive Therapy

- Jun 29, 2022
Hopkins Biotech Podcast I Hong Tang: Targeting the Common Side Effects of Cancer Therapies

- Jun 14, 2022
Fierce Biotech I After 3 years away, BIO marked by first-time handshakes

- May 31, 2022
BioSpectrum Asia I Our approach to managing the side effects of cancer therapy has evolved


- May 27, 2022
OnQuality Pharmaceuticals to Have Two Abstracts Published in the 2022 ASCO Annual Meeting Proceeding